Home Reports Studies and Analyses Content

New Study Reveals Gender-Disparity In Anti-TNF Treatment For Rheumatoid Arthritis

next article

15.06.2007

Subjective disease aspects ‘discounted’ in treatment decisions

Findings reported today at EULAR 2007, the Annual European Congress of Rheumatology (EULAR) in Barcelona, Spain, reveal a treatment disparity between female and male patients with rheumatoid arthritis (RA). Data from a study at the Karolinska Institute, Sweden, show that women receive anti-TNFs (very effective but expensive modern medications against this disease) at a higher perceived level of disease activity and when they are reporting more severe pain than their male counterparts.

Whilst some disease activity measurements were found to be higher for women than men, and self-reported disease activity by the patients themselves echoed this, the physicians’ global assessments showed little difference between the level of disease in the men and women of the study group.

Lead researcher Dr Ronald van Vollenhoven comments, “Women are known to have consistently worse long-term outcomes in rheumatoid arthritis than men. To date, it has been unclear if this is due to factors intrinsic to the disease or because of gender-related prescribing. Our study does not show a gender-bias as such, but does indicate that physicians to some extent ‘discount’ the subjective measures of disease activity, which we found to be higher in women, and let their decisions be driven almost solely by objective markers of the disease. As a result, women are receiving anti-TNFs at a higher level of disease symptoms than men. Because the goal of any treatment for RA must be to relieve the patients suffering, it is not clear that this approach is the right one.”

The study analysed baseline variables for the patients on RA who were started on anti-TNF treatment in the STURE Registry (the Stockholm TNF-alpha follow-up registry). When anti-TNFs were first prescribed to the 644 study participants, the level of their RA severity was logged, as measured according to Disease Activity Scale 28 (DAS28) which takes into account the severity of disease across the 28 joints most commonly affected by RA.

Each participant’s Erythrocyte Sedimentation Rate (ESR), which measures the level of inflammation, was also noted along with their Swollen Joint Count (SJC) and Tender Joint Count (TJC). Furthermore, both patients and their physicians completed a global assessment of disease activity, pain and physical activity (5 point scale questionnaire).

DAS28 scores at initiation of anti-TNF treatment were found to be significantly higher for women than for men (DAS28 was 5.53 for women, 5.04 for men, p=0.0006) and women had higher Tender Joint Counts (9.62 compared to 8.41 for males, p=0.066). The women in the study also had significantly higher ESR scores, although the authors suggest that this could be explained in part by the female hormone oestrogen, which affects tends to raise the ESR.

With regard to the more subjective self-reporting on the disease, through the patient-completed global health ratings, women also reported significantly worse global health (as measured by VAS and HAQ-disability index). However, the physician-completed global health ratings were equivalent for men and women.

Dr Ronald van Vollenhoven comments, “This study shows the importance of taking into account both objective and subjective measurement scores in treatment decisions. It is our hope that these data will help redress this imbalance and ensure equal prescribing and disease management for all.”

Rory Berrie | Source: alphagalileo
Further information: www.eular.org

next article